# US 2021/0275686 A1 · Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275686 A1
- Document ID: US20210275686A1
- Status: Published application
- Kind: A1
- Application number: 17/253,086
- Filed: 2019-06-13
- Published: 2021-09-09
- Earliest claimed: 2018-06-18
- Assignees: Bayer Aktiengesellschaft
- Applicants: Bayer Aktiengesellschaft
- Inventors: Sarah Anna Liesa JOHANNES; Hans-Georg LERCHEN; Beatrix STELTE-LUDWIG; Pascale LEJEUNE; Hannah JÖRISSEN; Christoph MAHLERT; Simone GREVEN; Stephan MÄRSCH; Stefanie HAMMER
- Web page: https://patentgrep.com/patent/US20210275686A1

## CPC

- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6867: {the tumour determinant being from a cell of a blood cancer}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/40: against enzymes
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to a new binder-drug conjugates with improved properties, to active metabolites of said ADCs and to processes for the preparation thereof. The invention particularly relates to antibody-drug conjugates (ADCs) with CXCR5 antibodies and selected KSP inhibitors. The present invention further relates to the use of said conjugates for the treatment and/ore prevention of diseases and to the use of said conjugates for the production of medicaments for the treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases.

## Claims

### Claim 1

Binder/active agent conjugates of general formula (I)
in which
X1 represents N,
X2 represents N and
X3 represents C;
or
X1 represents CH or CF,
X2 represents C and
X3 represents N;
or
X1 represents NH,
X2 represents C and
X3 represents C,
or
X1 represents CH,
X2 represents N and
X3 represents C,
R1 represents hydrogen or methyl,
R2 represents methyl, ethyl, —CH2—CH(CH3)2, —CH2—C(═O)OH or isopropyl,
R3 represents methyl, ethyl, —CH2—CH(CH3)2 or —CH2—C(═O)—NH2,
M represents the group
#—C(═O)—CH(CH3)—NH—C(═O)—(CH2)2-8—C(═O)-### or
#—C(═O)— (CH2)3—C(═O)-###,
n represents a number from 1 to 50,
AK2 represents a binder or a derivative thereof, preferably an antibody or an antigen-binding fragment
# represents the bond to the active agent and
### represents the bond to an N atom of a lysine side chain of the binder,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 2 (depends on 1)

The binder/active agent conjugates of general formula (I), according to claim 1, in which
X1 represents CH,
X2 represents C and
X3 represents N,
R1 represents hydrogen or methyl,
R2 represents methyl, —CH2—CH(CH3)2, —CH2—C(═O)OH or isopropyl,
R3 represents methyl, ethyl, —CH2—CH(CH3)2 or —CH2—C(═O)—NH2,
M represents the group
#—C(═O)—CH(CH3)—NH—C(═O)—(CH2)3—C(═O)-### or
#—C(═O)—(CH2)3—C(═O)-###,
n represents a number from 1 to 50,
AK2 represents a binder or a derivative thereof, preferably an antibody or an antigen-binding fragment,
# represents the bond to the active agent and
### represents the bond to an N-atom of a lysine side chain of the binder,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 3 (depends on 1, 2)

The binder/active agent conjugates of general formula (I), according to claims 1 and 2, in which
X1 represents CH,
X2 represents C and
X3 represents N,
R1 represents hydrogen or methyl,
R2 represents methyl or isopropyl,
R3 represents methyl or —CH2—C(═O)—NH2,
M represents the group
#—C(═O)—CH(CH3)—NH—C(═O)—(CH2)3—C(═O)-###,
n represents a number from 1 to 50,
AK2 represents a binder or a derivative thereof, preferably for an antibody or an antigen-binding fragment,
# represents the bond to the active agent and
### represents the bond to an N-atom of a lysine side chain of the binder,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 4 (depends on 1, 2, 3)

The binder/active agent conjugates of general formula (I), according to claims 1 to 3, in which
X1 represents CH,
X2 represents C and
X3 represents N,
R1 represents methyl,
R2 represents methyl,
R3 represents —CH2—C(═O)—NH2,
M represents the group
#—C(═O)—CH(CH3)—NH—C(═O)—(CH2)3—C(═O)-###,
n represents a number from 1 to 50,
AK2 represents a binder or a derivative thereof, preferably an antibody or an antigen-binding fragment,
# represents the bond to the active agent and
### represents the bond to an N-atom of a lysine side chain of the binder,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 5 (depends on 1, 2, 3, 4)

The binder/active agent conjugates of formula (I), according to claims 1 to 4,
in which
R1 represents methyl,
R2 represents methyl,
R3 represents —CH2—C(═O)—NH2,
M represents the group
#—C(═O)—CH(CH3)—NH—C(═O)—(CH2)3—C(═O)-###,
n represents a number from 1 to 20 and
AK2 represents an antibody or an antigen-binding antibody fragment thereof,
# represents the bond to the active agent and
### represents the bond to an N-atom of a lysine side chain of the antibody or of the antigen-binding antibody fragment thereof,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 6 (depends on 1, 2, 3, 4)

The binder/active agent conjugates of formula (I), according to claims 1 to 4, of the structure
in which
AK2 represents an antibody, bonded over an N atom of a lysine side chain and
n is 1 to 50,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 7 (depends on 6)

The binder/active agent conjugates according to claim 6, in which
n is 1 to 20,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 8 (depends on 6, 7)

The binder/active agent conjugates according to claims 6 and 7, in which
n is 1 to 8,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 9 (depends on 6, 7, 8)

The binder/active agent conjugates according to claims 6 to 8, in which
n is 4 to 8,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The binder/active agent conjugates according to claims 1 to 9, wherein
AK2 represents an anti-CXCR5 antibody or an antigen-binding fragment thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The binder/active agent conjugates according to claims 1 to 10, wherein
AK2 represents an anti-CXCR5 antibody selected from the group consisting of TPP 14511, TPP 14509, TPP 14499, TPP 14505, TPP14514 and TPP14495, or represents an antigen-binding antibody fragment thereof.

### Claim 12 (depends on 1, 2, 3, 4, 5)

The binder/active agent conjugates of general formula (I), according to claims 1 to 5 in which
R1 represents methyl,
R2 represents methyl,
R3 represents —CH2—C(═O)—NH2,
M represents the group
#—C(═O)—CH(CH3)—NH—C(═O)—(CH2)3—C(═O)-###,
n represents a number from 1 to 20 and
AK2 represents an anti-CXCR5 antibody selected from the group consisting of TPP 14511, TPP 14509, TPP 14499, TPP 14505, TPP 14514 and TPP 14495, or represents an antigen-binding antibody fragment thereof,
# represents the bond to the active agent and
### represents the bond to an N-atom of a lysine side chain of the antibody or of the antigen-binding antibody fragment thereof,
as well as their salts and solvates thereof and their salts of these solvates.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The binder/active agent conjugates according to claims 1 to 12, wherein AK2
(i) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 2, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 3 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 4, as well as a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 6, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 7 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 8,
(ii) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 12, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 13 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 14, as well as a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 16, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 17 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 18,
(iii) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 22, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 23 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 24, as well as a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 26, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 27 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 28,
(iv) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 32, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 33 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 34, as well as a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 36, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 37 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 38,
(v) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 42, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 43 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 44, as well as a variable region of the light chain (VL) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 46, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO:47 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 48, or
(vi) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH; SEQ ID NO: 51) comprising the variable CDR1 sequence of the heavy chain (H-CDR1), as shown by SEQ ID NO: 52, the variable CDR2 sequence of the heavy chain (H-CDR2), as shown by SEQ ID NO: 53 and the variable CDR3 sequence of the heavy chain (H-CDR3), as shown by SEQ ID NO: 54, as well as a variable region of the light chain (VL; SEQ ID NO:55) comprising the variable CDR1 sequence of the light chain (L-CDR1), as shown by SEQ ID NO: 56, the variable CDR2 sequence of the light chain (L-CDR2), as shown by SEQ ID NO: 57 and the variable CDR3 sequence of the light chain (L-CDR3), as shown by SEQ ID NO: 58,
or represents an antigen-binding fragment of these antibodies.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The binder/active agent conjugate according to any one of claims 1 to 12, wherein AK2
(i) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) as shown by SEQ ID NO: 1 as well as a variable region of the light chain (VL) as shown by SEQ ID NO: 5,
(ii) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) as shown by SEQ ID NO: 11 as well as a variable region of the light chain (VL) as shown by SEQ ID NO: 15,
(iii) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) as shown by SEQ ID NO: 21 as well as a variable region of the light chain (VL) as shown by SEQ ID NO: 25,
(iv) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) as shown by SEQ ID NO: 31 as well as a variable region of the light chain (VL) as shown by SEQ ID NO: 35,
(v) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) as shown by SEQ ID NO: 41 as well as a variable region of the light chain (VL) as shown by SEQ ID NO: 45, or
(vi) represents an anti-CXCR5 antibody comprising a variable region of the heavy chain (VH) as shown by SEQ ID NO: 51 as well as a variable region of the light chain (VL) as shown by SEQ ID NO: 55,
or represents an antigen-binding fragment of these antibodies.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The binder/active agent conjugate according to any one of claims 1 to 12, wherein AK2
(i) represents an anti-CXCR5 antibody comprising a region of the heavy chain as shown by SEQ ID NO: 9 as well as a region of the light chain as shown by SEQ ID NO: 10,
(ii) represents an anti-CXCR5 antibody comprising a region of the heavy chain as shown by SEQ ID NO: 19 as well as a region of the light chain as shown by SEQ ID NO: 20,
(iii) represents an anti-CXCR5 antibody comprising a region of the heavy chain as shown by SEQ ID NO: 29 as well as a region of the light chain as shown by SEQ ID NO: 30,
(iv) represents an anti-CXCR5 antibody comprising a region of the heavy chain as shown by SEQ ID NO: 39 as well as a region of the light chain as shown by SEQ ID NO: 40,
(v) represents an anti-CXCR5 antibody comprising a region of the heavy chain as shown by SEQ ID NO: 49 as well as a region of the light chain as shown by SEQ ID NO: 50, or
(vi) represents an anti-CXCR5 antibody comprising a region of the heavy chain as shown by SEQ ID NO: 59 as well as a region of the light chain as shown by SEQ ID NO: 60, or represents an antigen-binding fragment of these antibodies.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The binder/active agent conjugate according to any one of claims 1 to 15, wherein the antibody or the antigen-binding antibody fragment binds to an extracellular target molecule.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The binder/active agent conjugate according to any one of claims 1 to 16, wherein the antibody or the antigen-binding antibody fragment binds to an extracellular cancer target molecule.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The binder/active agent conjugate according to any one of claims 1 to 17 wherein the antibody or the antigen-binding antibody fragment after binding to an extracellular target molecule internalizes on the target cell through binding the target cell.

### Claim 19

A pharmaceutical composition comprising at least one binder/active agent conjugate according to one or more of the preceding claims in combination with an inert, nontoxic, pharmaceutically acceptable excipient.

### Claim 20

The binder/active agent conjugate according to any one or more of the preceding claims for use in a method for treatment and/or prophylaxis of diseases.

### Claim 21

The binder/active agent conjugate according to any one or more of the preceding claims for use in a method for treatment of hyperproliferative and/or angiogenic diseases.

### Claim 22

The binder/active agent conjugate according to any one or more of the preceding claims for use in a method for treatment of cancer and tumors.

### Claim 23

The binder/active agent conjugate according to any one or more of the preceding claims for use in a method for treatment of cancer and tumors in combination with one or more therapeutic compositions for cancer immunotherapy or with one or more active compounds directed against a molecular target from cancer immunotherapy.
